Didier Véron active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Leem | Director/Board Member | - | - |
Career history of Didier Véron
Former positions of Didier Véron
| Companies | Position | Start | End |
|---|---|---|---|
| IPSEN | Public Communications Contact | 2012-12-31 | 2018-11-30 |
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Public Communications Contact | 2010-08-24 | 2014-02-02 |
Training of Didier Véron
| Sciences Po | Undergraduate Degree |
Statistics
International
| France | 5 |
| United States | 2 |
Operational
| Public Communications Contact | 2 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| IPSEN | Health Technology |
| Private companies | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
| Leem | |
| Université de Paris XI Paris Sud | Consumer Services |
- Stock Market
- Insiders
- Didier Véron
- Experience
